Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $11.96 is 8.53% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 12.20||$ 21.20|
|Low:||$ 11.58||$ 11.02|
Company Description (as filed with the SEC)
We are a commercial biotechnology company leveraging our proven development and commercial capabilities as we seek to bring multiple medicines to patients. We are advancing innovative product opportunities in areas of large unmet need, based upon our target-to-disease approach to development and leveraging our core areas of expertise in gastrointestinal, or GI diseases and primary care, as well as in guanylate cyclase, or GC, pathways. Our first commercial product, linaclotide, is available to adult men and women suffering from irritable bowel syndrome with constipation, or IBSC, or chronic idiopathic constipation, or CIC, in certain countries around the world. Linaclotide is available under the trademarked name LINZESS® to adult men and women suffering from IBSC or CIC in the United States, or the U.S., and Mexico, and to adult men and women suffering from IBS-C in Japan. ... More ...
Nasdaq Official Price
Nov. 19, 2018
Nov. 19, 2018